Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [961]

Development and challenges for T-cell engagers as a novel treatment for lung...

Dr May-Lucie Meyer - Lausanne University Hospital, Lausanne, Switzerland

Development and challenges for T-cell engagers as a novel treatment for lung cancer and mesothelioma ( Dr May-Lucie Meyer - Lausanne University Hospital, Lausanne, Switzerland )

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC

Dr Miranda Gogishvili - High Technology Medical Centre, Tbilisi, Georgia

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC ( Dr Miranda Gogishvili - High Technology Medical Centre, Tbilisi, Georgia )

MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated...

Dr Adrian Sacher - Princess Margaret Cancer Center, Toronto, CA

MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer ( Dr Adrian Sacher - Princess Margaret Cancer Center, Toronto, CA )

Durvalumab plus chemotherapy improves survival in extensive-stage small cell...

Dr Lorenza Landi - National Cancer Institute Regina Elena, Rome, Italy

Durvalumab plus chemotherapy improves survival in extensive-stage small cell lung cancer regardless of tumour laterality ( Dr Lorenza Landi - National Cancer Institute Regina Elena, Rome, Italy )

Durvalumab improves survival and delays progression in limited-stage small cell...

Dr Eva Buchmeier - Hospitals of the City of Cologne gGmbH, Cologne, Germany

Durvalumab improves survival and delays progression in limited-stage small cell lung cancer ( Dr Eva Buchmeier - Hospitals of the City of Cologne gGmbH, Cologne, Germany )

Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung...

Dr Saumil Ganhdi - University of Texas MD Anderson Cancer Center, Houston, USA

Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung cancer ( Dr Saumil Ganhdi - University of Texas MD Anderson Cancer Center, Houston, USA )

Pembrolizumab plus chemotherapy delivers lasting benefit in early-stage NSCLC

Dr Margarita Majem - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Pembrolizumab plus chemotherapy delivers lasting benefit in early-stage NSCLC ( Dr Margarita Majem - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )

Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion...

Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China

Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion lung cancer ( Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China )

TQB2922 combination shows high response rates in EGFR-mutant lung cancer after...

Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China

TQB2922 combination shows high response rates in EGFR-mutant lung cancer after tyrosine kinase inhibitor resistance ( Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China )

SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR...

Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China

SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer ( Prof Yi-Long Wu - Guangdong Lung Cancer Institute, Guangzhou, China )

Sevabertinib shows manageable diarrhoea without impacting efficacy in HER2...

Prof Nicolas Girard - Institut Curie, Paris, France

Sevabertinib shows manageable diarrhoea without impacting efficacy in HER2-mutant lung cancer ( Prof Nicolas Girard - Institut Curie, Paris, France )

Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant...

Prof Nicolas Girard - Institut Curie, Paris, France

Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer ( Prof Nicolas Girard - Institut Curie, Paris, France )

More from ecancer